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Abstract
This commentary discusses a study on measurements of matrix metalloproteinase 9 (MMP-9) in
serum of pseudoxanthoma elasticum patients recently published in Journal of Molecular Medicine.
This study can be considered the typical "obstacle" to effective translational medicine as previously
documented in JTM journal. Although serum has been frequently proven as inappropriate sample
for determining numerous circulating MMPs, among them MMP-9, there are over and over again
studies, as in this case, that measure MMP-9 in serum. Comparative measurements in serum and
plasma samples demonstrated higher concentrations for MMP-9 in serum due to the additional
release from leukocytes and platelets following the coagulation/fibrinolysis process. From this
example it can be concluded that translating basic research discoveries into clinical tools needs a
more intensive exchange between basic biomedical research and clinical scientists already in an
early stage. Otherwise a lost of translation, as discussed in JTM journal, seems to be inevitable.
Commentary
Diekmann et al. [1] recently reported data in the Journal
of Molecular Medicine on the increased serum concentra-
tions of circulating matrix metalloproteinases 2 and 9
(MMP-2; MMP-9) in patients suffering from pseudoxan-
thoma elasticum. This genetic disorder, caused by muta-
tions in the transporter gene ABCC6, is characterized by
alterations in the extracellular matrix, especially in the
skin, retina, and the vascular system. The authors reported
that MMP-9 in serum was found both in male and female
patients about 2.5-times higher than that in healthy con-
trols, whereas MMP-2 was elevated only in female
patients. On this basis, the authors hypothesized that the
development of the symptoms of pseudoxanthoma elasti-
cum could be attributed to the action of MMPs, since
these enzymes are well known to be involved in the initial
step of damage and/or the following remodelling, repair-
ing processes of extracellular matrix [2]. The authors con-
cluded that the measurement of serum MMP-2 and MMP-
9 could be applied for non-invasive monitoring of matrix-
degradative processes in pseudoxanthoma elasticum. In
this respect, the use of MMP-2 and MMP-9 as surrogate
biomarkers suggested by Diekmann et al. [1] may be
appreciated as a nice example of translational medicine,
defined as "the transfer of new understandings of disease
mechanisms gained in the laboratory into the development of
new methods for diagnosis, therapy, and prevention and their
first testing in humans" [3] or "effective translation of the new
knowledge, mechanisms, and techniques generated by advances
in basic science research into new approaches for prevention,
diagnosis, and treatment of disease ....for improving health"
[4].
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The study of Diekmann et al. [1] deals with an interesting
topic and shows the potential of basic science discovery to
improve clinical medicine. However, a closer and accurate
re-examination of this "bench-to-bedside" example man-
ifests that Diekmann et al. [1] have neglected the opposite
"bedside-to-bench" effort of translational medicine as sec-
ond part of its "two-way road" principle [5]. According to
growing literature evidence demonstrating that blood
sampling strongly influences the measurement and recov-
ery of "true" circulating matrix metalloproteinases
(MMPs) and their tissue inhibitors (TIMPs), we would
like to draw attention on the preanalytical impact of
blood collection/handling methods in order to limit tech-
nical pitfalls that may lead to misinterpretations. In par-
ticular, the authors did not consider that serum was
demonstrated as inappropriate sample for measuring cir-
culating MMP-9. Noteworthy, the misuse of serum as
sample for determining circulating MMP-9 was frequently
considered inadequate, both in clinical and biochemical/
analytical journals [6-11]. It was additionally pointed out
that technical details of sampling and handling proce-
dures (like the time between venipuncture and centrifuga-
tion of blood samples as well as the use of different
anticoagulants) must be taken into consideration with
more attention and have to be reported due to their
known crucial influence on the concentrations and activa-
tion/inhibition patterns of MMP-9 [12,13]. Thus, the fun-
damental significance of blood processing as important
preanalytical determinant of accurate measurements of
really circulating MMPs in peripheral blood, especially for
MMP-9, has been clearly overlooked by Diekmann et al.
[1]. It is a typical example that may be considered as of
one of the significant "obstacles" to effective translational
medicine contributing to the "lost of translation" as well
documented in JTM journal [14].
To highlight the role and effects of preanalytical condi-
tions, we summarized in Figure 1 some of our own data of
MMP-2 and MMP-9 measurements in serum and plasma
samples collected under different conditions [15]. Briefly,
from 10 healthy adults (all with normal leukocyte count
and profile), venous blood samples were simultaneously
collected in plastic tubes (Monovette Systems, Sarstedt
AG, Nümbrecht, Germany). All subjects, informed about
the objectives of the study, participated on a voluntary
basis and provided informed consent. Tubes either with-
out additives or with kaolin-coated granulate as clot acti-
vator were used to prepare native serum (serum(-)) or
serum after enhanced coagulation (serum(+)), respec-
tively; tubes with lithium heparin or sodium citrate were
used to collect plasma samples. The blood specimens
were centrifuged within 30 min after venipuncture at
1600 × g and 4°C for 15 min and the supernatants were
carefully removed and stored at -80°C until analysis.
MMPs were measured in duplicates with the Fluorokine
MultiAnalyte Profiling assay system (R&D Systems, Min-
neapolis, MN, USA) on a Luminex 100 Bioanalyzer
(Luminex Corp., Austin, TX, USA). The MMP assays
detect, according to manufacturer's instructions, the corre-
sponding pro-, mature, and tissue inhibitor of metallo-
proteinase (TIMP)-1-complexed MMPs. With regard to
the measurements of MMPs in the different types of sam-
ples, the percentage analytical coefficients of variation cal-
culated from the duplicate values were between 5.9% and
8.9% for MMP-2 and 4.1% and 8.4% for MMP-9, respec-
tively.
Figure 1A shows that higher MMP-9 concentrations were
found in serum in comparison with plasma samples.
Moreover, the highest values of MMP-9 were observed in
serum(+) samples obtained after kaolin-enhanced clotting.
They were up-to 4 times higher compared with those in
serum(-)  samples collected without clot activator and
about 15 times higher than those in citrate plasma. In
contrast, the MMP-2 concentrations were influenced to a
less extent by the blood collection procedures (Figure 1B);
in fact, in citrate plasma, MMP-2 concentrations were
about 10% lower than in the other three kinds of samples.
For these reasons and according to literature, plasma sam-
ple (e.g., obtained with citrate as anticoagulant) has been
suggested to be the sample of choice for measuring circu-
lating MMP-9 [16-18].
These data underline that MMP-9 concentrations detected
in serum do not correspond to the true concentrations of
MMP-9 circulating in blood. In fact, it has been demon-
strated that increased MMP-9 concentrations in serum, in
comparison to plasma samples, arise from the secretion of
MMP-9 linked to platelet and leukocyte degranulation
during coagulation/fibrinolysis processes (epiphenome-
non greatly enhanced by kaolin-granulate) [8,13]. It is
noteworthy to highlight that both mRNA and protein of
ABCC6, causative of the pseudoxanthoma elasticum, have
been identified in leukocytes, macrophages, and lym-
phocytes [19,20], and that all these white blood cells
abundantly contain MMP-9 [21,22].
Preconditions for a reasonably feasible extrapolation
from serum to plasma data would be based on strong cor-
relations between serum and plasma values and equal
ratios of serum to plasma values in controls and the dis-
eased cohort (e.g., equal slopes in the regression equa-
tions between the two kinds of samples in controls and
the diseased patients). Although correlations of MMP-9
and MMP-2 between serum and plasma samples exist in
patients with gestational hypertension and periodontal
disease [23] (but they are obviously unknown for pseu-
doxanthoma elasticum patients), comparative measure-
ments in other patient groups [24] showed that the high
unspecific "background" concentration of MMP-9 inJournal of Translational Medicine 2009, 7:87 http://www.translational-medicine.com/content/7/1/87
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serum obviously was not related to the true pathological
process of interest, thus impairing the potential diagnostic
performance of MMP-9 biochemical evaluation [24].
Moreover, the use of serum collected under similar condi-
tions both in healthy and diseased patients is surely not
suited to circumvent that misleading procedure especially
since the technical details of sampling procedures (e.g.,
the presence of clot activator in serum tube, the time
among sample collection, centrifugation and assay [11])
were not clearly described by Diekman et al. [1]. Further-
more, the potential difference in leukocyte counts and
profiles between patients affected by pseudoxanthoma
elasticum and healthy subjects may significantly affect the
release from white blood cells and platelets during clot-
ting and subsequent recovery in serum of MMP-9. These
preanalytical pitfalls can be avoided by the use of more
standardized conditions and the use of plasma samples
[15,16]. Thus, if this known "bedside" experience of clin-
ical scientists concerning preanalytical issues of blood
sampling as important part of a study design is disre-
garded, it cannot be expected that serum MMPs result in
reliable surrogate biomarkers [1].
Conclusion
In conclusion, to ensure an effective translation between
basic biomedical research and clinical practice, appropri-
ate preanalytical procedures of sample collection and
handling have to be laid down; this is particularly true
when investigating the potential diagnostic power of a
biomarker in clinical trials [25,26]. This principle should
be considered already in an early stage to transfer basic sci-
ence discoveries into new clinical tools. In addition,
molecular medicine journals should recognize and sup-
port with their publication policy that important, though
neglected issue. In particular, studies on MMPs and their
tissue inhibitors TIMPs in physio-pathological conditions
should address these preanalytical effects to avoid pitfalls
and misinterpretations due to crucial interfering factors of
blood processing, not properly taken into consideration
[11].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KJ had the idea and was responsible for drafting the man-
uscript, FM and LM contributed to the writing and critical
revision of the manuscript. All authors read and approved
the manuscript.
References
1. Diekmann U, Zarbock R, Hendig D, Szliska C, Kleesiek K, Gotting C:
Elevated circulating levels of matrix metalloproteinases
MMP-2 and MMP-9 in pseudoxanthoma elasticum patients.  J
Mol Med 2009, 87:965-970.
2. Malemud CJ: Matrix metalloproteinases (MMPs) in health and
disease: an overview.  Front Biosci 2006, 11:1696-1701.
3. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM,
Johnson SB, Catanese V, Tilson H, Getz K, et al.: Central challenges
facing the national clinical research enterprise.  JAMA 2003,
289:1278-1287.
4. Fontanarosa PB, DeAngelis CD: Basic science and translational
research in JAMA.  JAMA 2002, 287:1728.
5. Marincola FM: Translational medicine: a two-way road.  J Transl
Med 2003, 1:1.
6. Zucker S, Cao J: Measurement of matrix metalloproteinases in
serum of patients with melanoma: snarled in technical pit-
falls.  Clin Cancer Res 2005, 11:5069-5070.
7. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos
JE:  Methodological issues affecting the determination of
plasma matrix metalloproteinase (MMP)-2 and MMP-9
activities.  Clin Biochem 2005, 38:410-414.
8. Mannello F, Tonti GA, Tanus-Santos JE, Gerlach RF: Silicate
increases the release of MMP-9 forms in peripheral blood:
why gelatin zymography differs significantly in citrate
plasma and serum obtained with or without clot activators.
Clin Chem 2007, 53:1981-1982.
9. Mannello F, Tonti GA, Canestrari F: The 'never-ending story' of
the influence of blood specimen collection methods affecting
the concentration, the zymographic profile and the useful-
ness of matrix metalloproteinases and their tissue inhibitors
in multiple sclerosis diagnosis/prognosis: a landmark for lim-
iting the misuse of serum samples.  Mult Scler 2007, 13:687-690.
Effect of blood sampling on MMP-9 (A) and MMP-2 (B) con- centration in serum and plasma Figure 1
Effect of blood sampling on MMP-9 (A) and MMP-2 
(B) concentration in serum and plasma. Values are 
given as mean values and their 95% confidence intervals rela-
tive to the mean value (=100%) of concentrations measured 
in serum(+) samples from ten healthy adults. Statistical analy-
ses were carried out by Student's t-test of paired data.
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